Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Charles Fruchart

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Cardiovascular Diabetology|October 6, 2017
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemiaJean-Charles Fruchart
International Journal of Clinical Practice. Supplement|November 12, 2002
The science behind statins and fibratesJean-Charles Fruchart
Presse Medicale (Paris, France : 1983)|October 16, 2002
[Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective]Jean-Charles Fruchart
The American Journal of Cardiology|December 6, 2007
Novel peroxisome proliferator activated receptor-alpha agonistsJean-Charles Fruchart
Cardiovascular Diabetology|June 1, 2013
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsJean-Charles Fruchart
Nature Clinical Practice. Cardiovascular Medicine|March 16, 2007
Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women?Jean-Charles Fruchart
Atherosclerosis|April 24, 2009
Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular diseaseJean-Charles Fruchart
Diabetes|July 28, 2005
Therapeutic roles of peroxisome proliferator-activated receptor agonistsBart Staels, Jean-Charles Fruchart
Medecine Sciences : M/S|July 3, 2003
[PPAR gamma: a major nuclear receptor in adipogenesis]Philippe Gervois, Jean-Charles Fruchart
Current Atherosclerosis Reports|October 4, 2002
HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials?Jean-Charles Fruchart, Patrick Duriez
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Cardiovascular Diabetology|October 6, 2017
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemiaJean-Charles Fruchart
International Journal of Clinical Practice. Supplement|November 12, 2002
The science behind statins and fibratesJean-Charles Fruchart
Presse Medicale (Paris, France : 1983)|October 16, 2002
[Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective]Jean-Charles Fruchart
The American Journal of Cardiology|December 6, 2007
Novel peroxisome proliferator activated receptor-alpha agonistsJean-Charles Fruchart
Cardiovascular Diabetology|June 1, 2013
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsJean-Charles Fruchart
Nature Clinical Practice. Cardiovascular Medicine|March 16, 2007
Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women?Jean-Charles Fruchart
Atherosclerosis|April 24, 2009
Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular diseaseJean-Charles Fruchart
Diabetes|July 28, 2005
Therapeutic roles of peroxisome proliferator-activated receptor agonistsBart Staels, Jean-Charles Fruchart
Medecine Sciences : M/S|July 3, 2003
[PPAR gamma: a major nuclear receptor in adipogenesis]Philippe Gervois, Jean-Charles Fruchart
Current Atherosclerosis Reports|October 4, 2002
HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials?Jean-Charles Fruchart, Patrick Duriez
Pageof 17